BioNTech SE ADR (NASDAQ:BNTX) traded at $113.50 at last check on current trade day and made an upward move of 18.46% on its previous day’s price.
BioNTech SE ADR has a market cap of $27.28 billion and is expected to release its quarterly earnings report in July.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 143.61M, with a low of 82.26M and a high of 406.4M. The median projection represents growth squeezing down to 11.59% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 2.03B, or -26.09% down from figures reported last year.
Based on estimates by 13 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the BioNTech SE ADR (BNTX) stock as a Hold, while 9 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 2 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 16.58% off its SMA20 and 15.81% from its 50-day simple moving average. The RSI (14) is pointing at 64.93 while the volatility over the past week is 3.00% and jumps to 3.17% over the past one month. The beta value is 1.29, while the average true range (ATR) is currently pointing at 5.77. The average price target for the stock over the next 12 months is $122, with the estimates having a low of $110 and a high of $134. These price ends are 3.08% and -18.06% off the today’s price level respectively, although investors could be excited at the prospect of a -7.49% if the BNTX share price touches on the median price of $122.
